News from engene A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 29, 2019, 15:28 ET enGene Appoints José M. Lora, PhD as Chief Scientific Officer

MONTRÉAL and BOSTON, May 29, 2019 /CNW/ - enGene Inc., the high growth biotechnology company developing the Gene Pill™ - a robust, proprietary non-viral vector platform to deliver gene therapies via...


Jul 16, 2018, 08:00 ET enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President

MONTRÉAL and BOSTON, July 16, 2018 /CNW/ - enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs, including...


Oct 31, 2017, 09:00 ET enGene named Company of the Year by BIOTECanada

Prestigious Gold Leaf Award recognizes enGene's leadership and achievements MONTREAL, Oct. 31, 2017 /CNW/ - enGene Inc., a biotechnology company focused on the development of a proprietary Gene...


Jul 10, 2017, 06:00 ET Industry Veteran Mr. Steve Gannon Joins enGene's Board of Directors

MONTREAL, July 10, 2017 /CNW/ - enGene Inc., a biotechnology company focused on the development of a proprietary oral gene therapy platform, today announced the appointment of Steve Gannon as an...


May 01, 2017, 06:00 ET enGene announces appointment of Theresa Podrebarac, MD, as Chief Medical Officer

MONTREAL, May 1, 2017 /CNW/ - enGene Inc. announced today that Theresa Podrebarac, MD, has joined the company as Chief Medical Officer. In her new position, Dr. Podrebarac will be responsible for...


Apr 28, 2017, 06:00 ET enGene's mucosal gene delivery platform is successful in targeting PD-L1 expression in the gut, demonstrating effective treatment of colitis and GvHD in preclinical models

enGene's proprietary PD-L1 gene therapy is being developed as potential novel therapy for acute GvHD Late-breaking abstract on preclinical data from PD-L1 program will be presented at Digestive...


Jan 11, 2016, 19:00 ET Takeda And enGene Establish Strategic Alliance to Develop Novel Therapeutics For Gastrointestinal Diseases

OSAKA, Japan and MONTREAL, Jan. 11, 2016 /CNW Telbec/ - Takeda Pharmaceutical Company Ltd. (TSE: 4502) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize...


Oct 14, 2015, 08:00 ET enGene announces strategic collaboration with Johnson & Johnson innovation to develop novel gene delivery products for inflammatory bowel disease

MONTREAL, Oct. 14, 2015 /CNW Telbec/ - enGene, Inc. a gene therapy company focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced...


Jan 26, 2015, 08:40 ET enGene raises CAD 13.5 million (US$11.5M) to develop intestinal gene delivery platform

MONTRÉAL, Jan. 26, 2015 /CNW Telbec/ - enGene Inc., a Montréal-based biotechnology enterprise developing an innovative platform technology for delivering genes to cells lining the gastrointestinal...